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Induction of Prostaglandin Release from Macrophages by Bacterial Endotoxin
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This review summarizes the role of the monocytic responses to lipopolysaccharide as it relates to
periodontal disease severity. Data are presented which illustrate that the levels of prostaglandin E2
(PGE2) secreted by systemic peripheral blood monocytes in culture, in the presence of bacterial
endotoxins, are highly correlated with the levels observed in the gingival crevicular fluid. Further-
more, the different periodontal diagnostic categories have varying levels of monocytic and crevicular
fluid PGE2, in juxtaposition with clinical disease severity. These data are consistent with the concept
that there is close synchrony between the systemic responsiveness of peripheral blood monocytes
with regard to prostanoid synthesis and the local levels of mediator present within the gingival
crevice.
In recent years an altered central dogma regarding the patho- which the host response emerges as the dominant effect mod-
ifier in disease expression. Recent molecular and cellular datagenesis of periodontitis has emerged [1, 2]. Periodontal diseases
are widespread, but severe disease appears to affect only have improved our understanding of the inflammatory and im-
mune mechanisms that result in the destruction of connective7%–14% of the population [3]. Periodontitis is multifactorial
in nature with regard to potential etiologic factors and effect tissue, including ligament and bone. This sequence can be
considered a central pathway that is common to most forms ofmodifiers. Since the classic 1965 article by Lo¨e et al. [4], the
microbial plaque has been considered the cause of periodontal disease but is activated or inhibited to varying degrees by
various components of the host response and exposure factors.diseases. Although certain gram-positive organisms have been
associated with disease, the preponderance of data indicates This pathway can be activated in cyclic fashion, as manifested
by clinical progression or remission of disease activity. Thethat the gram-negative anaerobic species are the dominant
pathogens [5]. However, recent data support the concept that central pathway that links microbial exposure to connective
tissue destruction involves monocytic (Mf) activation.microbial plaque is a necessary etiologic factor that is at the
origin of the causality pathway but it is not sufficient to explain In this model the monocytic activation by lipopolysaccharide
(LPS; endotoxin) is a critical regulatory event that ultimatelythe presence, absence, or severity of disease. It is likely that
one or more virulent clonal types of periodontal pathogens modulates connective tissue catabolism. The purpose of this
article is to summarize the data regarding the role of monocyticwithin the microbiota effectively evade host defenses to present
an invasive challenge. Once the defenses are challenged, how- secretion of prostaglandin E2 (PGE2 ) in various forms of peri-
odontal diseases. New data are shown linking the local mono-ever, the quality of the host immunoinflammatory response
appears to ultimately determine the severity and extent of dis- cytic production of PGE2 within the periodontal tissues (as
measured in the gingival crevicular fluid, or GCF) and theease expression.
The difference among people in terms of the nature of the responsiveness of systemic monocytes (as determined with use
of peripheral blood monocytes in culture). Evidence is providedimmunoinflammatory response is a potential determinant of the
variability in the expression of disease observed within the to suggest that the monocytic responsiveness to LPS, as re-
flected in the amount of PGE2 secreted, may be a key regulatorpopulation. The current concepts of pathogenesis have ex-
tended the model from a plaque-dominated process to one in of disease expression. Furthermore, the magnitude of the mono-
cytic responsiveness is simultaneously expressed locally and
systemically. This coordination of monocytic conditions in the
periodontal and systemic blood compartments suggests a sys-This article is part of a series of papers presented at a symposium entitled
temic origin for the observed local effects.‘‘Molecular Mechanisms of Microbial Host Cell Interactions in Periodontal
Disease’’ that was held on 14–18 March 1997 in St. Petersburg, Florida.
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affinity receptor for the LPS–LPS binding protein complex. tent with an altered microbial burden and increased susceptibil-
ity to further breakdown. As expected, at moderate to deepWhen activated CD14 initiates a complex signaling cascade,
phospholipase A2 is activated to release arachidonic acid plus (i.e., 4–11 mm) periodontal sites in patients with AP, there is
a significant elevation in GCF-PGE2 levels as compared withlysophospholipids from membrane phospholipid pools. Arachi-
donic acid is subsequently converted by the action of a cyclo- those at shallow sites (71.0 { 11.8 ng/mL vs. 49.0 { 5.2
ng/mL). Furthermore, the mean GCF-PGE2 level in patients inoxygenase (PGH2 synthase) to PGE2 , which appears extracellu-
larly. Transcriptional regulatory factors are activated and whom periodontal disease progression is detected, as defined
by attachment loss of ⁄3 mm at one or more sites over a 6-ultimately result in the transcription, synthesis, and secretion
of several proinflammatory molecules, such as IL-1b, TNF-a, month period after initial therapy, is significantly higher than
in subjects who have no clinical signs of disease activity (113.4and IL-6. These four mediators target monocytes and fibro-
blasts to secrete matrix metalloproteinases to degrade collagen { 9.0 ng/mL vs. 50.1 { 7.1 ng/mL; P  .00001).
This observation holds true at the time of detection of attach-and glycosaminoglycans, thereby destroying the ligament and
extracellular matrix. These mediators also act directly on bone ment loss as well as 6 months before this time point. Further-
more, at sites undergoing periodontal attachment loss, the GCF-cells to induce osteoclast formation and activation.
Clinically, activation of this pathway ultimately results in PGE2 level is 305.6{ 56.5 ng/mL, showing a fivefold to sixfold
elevation in comparison with the level at nonprogressing sites.increased attachment and bone loss. Activation of this pathway
can be detected biochemically, prior to any clinical sign of Thus, biochemically the GCF-PGE2 level represents a contin-
uum from health to progressing disease as the PGE2 level in-periodontal disease progression. Furthermore, experimental
disruption in the central components of this host pathway abates creases from 30 ng/mL to 300 ng/mL, a 10-fold increase in
mediator level. Levels above 60–100 ng/mL reflect increasedclinical disease progression [4]. It should be emphasized that
this description of an LPS-triggered cascade of events is a risk or subclinical destruction. However, these values refer to
normal, otherwise healthy people who have either gingivitis orgreat oversimplification of a complex series of occurrences and
divergent pathways. AP. Some patients, such as those with diabetes or early onset
disease, appear to have an altered GCF-PGE2 profile, which isIf one is to test this model of pathogenesis, then logically the
differences in disease expression observed in different people consistent with increased risk for disease progression and a
parallel upregulated systemic monocytic state.should be reflected in the relative degree of pathway activation.
In this report we focus on the monocytic release of PGE2 in
response to LPS, examining the differences in PGE2-release
profiles among patients with various forms of disease and in GCF-PGE2 in High-Risk Patients
health.
An exaggerated GCF-PGE2 inflammatory response has been
documented in several high-risk patient groups, as compared
PGE2 and Periodontal Disease Activity and Severity to that among otherwise healthy patients with gingivitis and
AP [9, 11]. These high-risk categories include patients withSince original reports in 1986, considerable additional data
have confirmed that the PGE2 level within the gingival crevi- early onset periodontitis (EOP), refractory periodontitis (RefP;
American Academy of Periodontology [AAP] type V), insulin-cular fluid can be considered a reliable biochemical marker
for periodontal disease activity and severity [6–9]. During dependent diabetes mellitus (IDDM)–associated AP (IDDM-
AP), and terminal dentition periodontitis (TDP, i.e., extremelythe induction of experimental gingivitis in humans, there is
an increase in PGE2 levels in GCF (GCF-PGE2 levels), from severe periodontitis requiring multiple extractions). Thus, these
subjects with different forms of disease seemed to share a20.5 { 7.6 ng/mL (mean { SE, periodontal health) to 53.5
ng/mL after 4 weeks [10]. This GCF-PGE2 level determined propensity for developing severe forms of periodontal disease
and also had elevated GCF-PGE2 levels. This observationat 4 weeks is comparable to that measured cross-sectionally
among patients with adult periodontitis (AP; 58.7 { 11.2 prompted us to examine whether the production of PGE2 by
peripheral blood monocytes from these patients may be en-ng/mL) [10, 11] and is coincident with the attainment of
clinical inflammation. Thus, in a cross-sectional comparison, hanced in response to LPS challenge, as compared with such
production in periodontally healthy individuals.the GCF-PGE2 level expressed as a mean patient value does
not seem to be a sensitive discriminator between established The underlying hypothesis was that monocytes from patients
who had more severe disease or were actively losing attachmentgingivitis and stable or nonprogressing AP.
Furthermore, if one considers only shallow periodontal sites at the time of sampling would secrete more inflammatory mark-
ers (with PGE2 as a representative mediator) than would mono-(i.e., 0–3 mm) in patients with AP, the GCF-PGE2 levels are
significantly higher than those of healthy subjects (49.0 { 5.2 cytes from subjects with less severe forms of disease, inactive
disease, or no disease. We hypothesized that this would beng/mL vs. 20.5 { 7.6 ng/mL). Thus, periodontally healthy
sites in patients with AP have higher GCF-PGE2 levels than reflected as a shift to the left in the dose-response curve when
examining the PGE2 response vs. the LPS dosage; thus, at anyclinically healthy sites in periodontally healthy subjects, consis-
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level of LPS (including zero) patients with more severe disease patients present with multiple teeth that are hopelessly involved
with periodontitis and require extractions. The subjects withwould secrete more PGE2 per monocyte.
We also hypothesized that the systemic responsiveness of TDP included eight with AP and eight with generalized EOP,
according to the EOP criteria of Gunsolley et al. [14]. Finally,these monocytes would regulate the amount of PGE2 produced
locally in the periodontal pocket, as measured in the GCF. The the last group of interest included 13 patients with paroxysmal
nocturnal hemoglobinuria [15], a condition in which patientshalf-life of gingival monocytic cells is about 18 days. Thus,
any systemic basal responsiveness would be expected to even- lack monocytic CD14 because of an impaired ability to synthe-
size the glycerolphosphatidyl inositol anchor protein thattually be manifest locally, since LPS is an omnipresent chal-
lenge in the subgingival periodontal pocket. For this reason, attaches the CD14 receptor onto the cell membrane. Thus,
monocytes from these individuals lack the membrane-bound,we also examined the potential association between the levels
present within the GCF compartment and that produced by high-affinity LPS–LPS binding protein receptor, CD14. As
will be shown and appears elsewhere [15], monocytes frommonocytes in culture upon LPS stimulation at a fixed subopti-
mal concentration (0.03 mg/mL). In effect, we sought to test these individuals have an impaired ability to respond to bacte-
rial endotoxin with respect to mediator production.our 1993 hypothesis that the patient’s monocytic mediator re-
sponse to LPS challenge was a key determinant of disease
expression [12].
GCF Sampling and Analysis
Materials and Methods
GCF was collected with Periopaper filter strips (Pro Flow,
Patient Selection Amityville, NY), and the volume was quantitated with a cali-
brated Periotron 6000 instrument (Pro Flow). The concentration
This report includes data from a total of 209 subjects di-
of PGE2 within the GCF was determined by means of RIAsvided into 7 main diagnostic categories: health (n  34), AP
or ELISAs. Since the procedures for GCF collection, storage,
(n  66), EOP (n  22), RefP (n  24), IDDM-AP (n  34),
and analysis have previously been described [8, 16–18], only
TDP (n  16; discussed below), and paroxysmal nocturnal
a brief summary of the sampling technique and analysis is
hemoglobinuria (n  13). All patients except those with
presented. The interproximal area between the two most poste-
IDDM-AP or paroxysmal nocturnal hemoglobinuria were free
rior teeth in each quadrant was selected for GCF sampling.
of systemic conditions or medications known to affect in-
Four filter strips, one in each quadrant, were used for each
flammatory or periodontal status. Some data from most of
patient. The preselected sites were isolated with cotton rolls
these patients have been reported previously [6–8, 10–13].
and air-dried, and then the GCF filter strips were placed into
This report provides a reanalysis of previous data and a master
the periodontal pocket until visibly moistened. After their re-
compilation of existing patients, including new patients added
moval, the volume was determined with the Periotron 6000.
since our original publications. Specifically, data demonstra-
Immediately afterward, the collected samples were wrapped in
ting dose-response curves between LPS concentration and
aluminum foil, placed into screw-top cryovials, and transferred
monocytic secretion of PGE2 have been published for 21 into liquid nitrogen. All GCF samples were maintained in liquid
healthy patients [8], 21 patients with AP [8], 25 patients with
nitrogen until the assays were performed. Prior to assay, each
IDDM-AP [8], and 16 patients with TDP [9]. For the purposes
filter strip was eluted and independently analyzed for PGE2 ,of this report, data concerning monocytic release of PGE2 expressed as a GCF-PGE2 concentration in ng/mL. The meanare shown for the different patient groups using a single,
GCF-PGE2 concentration for each patient represents the aver-submaximal LPS concentration for stimulating Mf in culture,
age for four sites.
adding new patients to the previously published data set.
The subjects with EOP include 22 patients who met the
criteria described by Gunsolley et al. [14]. Patients with AP
were subdivided according to type of disease (AAP types I to Monocyte Isolation and Stimulation with LPS
IV) and by the pooling of types I and II (n  36) as well as
types III and IV (n  30), on the basis of similarities in GCF The monocytic secretion of PGE2 in the peripheral blood
of each patient was evaluated following monocyte isolation,and monocytic secretory patterns. RefP (AAP type V) is de-
fined by Collins et al. [13]. Patients with IDDM-AP (AAP culturing in the presence of LPS, and determination of PGE2
concentration in the supernatant, with use of the methods de-types I and II [n  9] and types III and IV [n  25]) are
characterized in detail elsewhere [14, 15]. Recently, a new scribed earlier [8, 9, 16]. A standard venipuncture technique
was used to collect 40 mL of whole blood in heparinizedperiodontitis category has been suggested: TDP, as adapted
from the prosthodontic literature [9]. This refers to extremely tubes, and mononuclear cells were isolated with use of Ficoll-
Hypaque density gradients (Sigma Chemical, St. Louis), fol-severe forms of AP and EOP that are at a transition stage
between severe periodontitis and edentulism. Basically, these lowed by adherence to plastic culture wells. Mononuclear cells
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ditioned C18 column (Sep-pak, Waters Inc., Marlborough, MA).
The column was sequentially washed with 20.0 mL of 15%
ethanol, 20 mL of petroleum ether, and the prostanoids eluted
with 10 mL of methyl formate. The methyl formate was evapo-
rated to dryness under nitrogen and dissolved in HPLC buffer
(30% acetonitrite and 17-mM H3PO4 ). The PGE2 was resolved
isocratically on a reverse-phase (RP) Speri-5, RP-18, 100 1
4.6-mm, 5-m column after passing through an RP-18, 7 precol-
umn at a flow rate of 1 mL/min. Prostaglandins were detected
at 192 nm and quantitated by an in-line scintillation counter
(Flow-one, Inus Systems, Tampa, FL). Peak areas were inte-
grated, corrected for recovery, and expressed relative to cell
number or DNA content for comparisons.Figure 1. Basal (no lipopolysaccharide challenge) secretion of
prostaglandin E2 (PGE2 , measured in counts per minute [cpm]) from
isolated peripheral blood monocytes from periodontally healthy con-
trols (Control; n  11) and from patients with adult periodontitis Results
(AP; n  5), refractory periodontitis (RefP; n  8), and early onset
periodontitis (EOP; n  10). Unstimulated monocytes from subjects Monocyte Secretion of PGE2 in Unstimulated
with RefP and EOP secrete significantly higher amounts of PGE2 and LPS-Stimulated Cultures
than do those from pooled control subjects and patients with AP
(P  .01 for RefP vs. AP / control and P  .05 for EOP vs. AP / In a subset of patients, monocytes were preincubated in the
control). Standard error bars are shown. presence of tritiated arachidonic acid, and the release of PGE2
was monitored by extraction, separation by HPLC, and quanti-
tation by scintillation counting. The release of radioactive PGE2
into the media from unstimulated monocytes is shown in figurewere resuspended in RPMI medium in the presence of a 10%
pooled human antibody serum source of LPS-binding protein 1. As can be seen, the basal secretion of PGE2 in patients
with EOP and RefP is significantly higher than that in healthyand 1% penicillin/streptomycin at 377C in 5% CO2 . Isolated
monocytes were placed in short-term culture with varying subjects or patients with AP. There is no difference in the level
of PGE2 secreted in healthy controls vs. patients with AP. Thus,amounts of LPS (Porphyromonas gingivalis and Escherichia
coli, over a dose-response range of 0.003 to 3.0 mg/mL) for freshly isolated, unstimulated monocytes in subjects with EOP
or RefP appear to be ‘‘activated or primed’’ in the peripheralPGE2 quantitation. The supernatants were harvested after over-
night incubation (12–18 hours) and analyzed by RIA or ELISA blood of these subjects, as compared with such monocytes in
healthy subjects or those with AP. This is reflected in thefor the amount of PGE2 present.
In certain experiments, monocytes were preincubated with approximate ninefold to 10-fold elevation of monocytic PGE2
in the absence of exogenous LPS.tritiated arachidonate–human serum albumin conjugate. This
resulted in uptake of arachidonate into preexistent phospholipid Furthermore, monocytes from patients with EOP or RefP
secrete more PGE2 in response to LPS challenge throughoutpools. Following LPS stimulation, supernatants from these la-
beled cells were subjected to reverse-phase high-pressure liquid the entire dose-response curve (figure 2), as compared to AP
or healthy controls. In these data, the elevated PGE2 secretionchromatography (HPLC), and the amount of radiolabeled PGE2
was determined with an in-line scintillation counter, as de- throughout the LPS dose-response appears to be largely due
to differences in basal secretion. In this early experiment andscribed earlier [19]. In brief, adherent monocytes were released
(0.01 mM EDTA-PBS [pH, 7.4] at 47C) and pelleted. Cells in subsequent experiments, no significant difference in the
monocytic release of PGE2 has been observed in terms of thewere prelabeled by incubating with
3H arachidonic acid–hu-
man serum albumin conjugate in RPMI medium, washed, and response in healthy patients or those with gingivitis vs. patients
with moderate to severe AP. However, in both EOP and RefP,replated at 108 cells/mL in RPMI medium supplemented with
10% pooled antibody serum (Sigma, St. Louis) and 1% penicil- there is an increase in the maximum level secreted (about
twofold to threefold) and a shift to the left in the dose-responselin/streptomycin. After incubation, monocyte supernatants
were extracted as described by Powell [19]. To each sample, curve. This indicates not only that monocytes from these two
patient groups secrete higher levels of PGE2 but that low levels10,000 counts per minute (cpm) of
3H-6K-PGF1a was added
as internal standard. To 0.5 mL of media, 1.0 mL of ethanol of LPS, which are below the activation threshold of control or
AP monocytes, trigger PGE2 secretion in these subjects. Thus,was added and centrifuged.
The pellet was washed with 0.5 mL of ethanol, the superna- even relatively low levels of endotoxin might be expected to
result in PGE2 secretion in the GCF in these individuals.tants were pooled, and the sample was adjusted with water to
15% ethanol, with a final volume of 15 mL. Acetic acid was This early observation led to a series of experiments involv-
ing many different groups of patients to determine whether thisadded to a pH of 3.0, and the sample was passed over a precon-
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duced monocytic secretory capacity and secrete only 28.5 {
5.8 ng of PGE2 per mL (P  .00002, in comparison with the
level for pooled MfN subjects). This is designated as a Mf0
trait for these CD14-deficient subjects. The GCF-PGE2 levels
for the MfN subjects are consistent with the local increase in
bacterial burden associated with AP of AAP types I–II (44.4
{ 5.8 ng/mL) and III–IV (58.7 { 11.2 ng/mL).
This finding suggests that the significantly lower GCF-PGE2
levels seen in healthy persons (22.5 { 4.8 ng/mL) than in
pooled subjects with AP of AAP stages I–IV (P  .002) are
a reflection of the lower LPS burden associated with optimal
periodontal health. It is interesting that a reasonable linear
correlation exists among the patients and that the healthy indi-
viduals are outliers at this particular LPS concentration. This
Figure 2. Systemic monocytic prostaglandin E2 (PGE2 ) secretion suggests a significant positive association between the GCF-
from patients with gingivitis and adult periodontitis (American Acad-
PGE2 level and the systemic monocytic response. This conceptemy of Periodontology [AAP] stages I–IV; n  16; l), refractory
is further substantiated by additional patient data.periodontitis (AAP stage V; n  8; j), and early onset periodontitis
(n  10; m). There is a significant difference over the entire dose-
response curve (with 0–3.0-mg/mL doses of LPS [lipopolysaccharide
Monocytic and GCF-PGE2 Levels in Patientsisolated from Porphyromonas gingivalis]) when monocytic PGE2 se-
with RefP and EOPcretions from patients with gingivitis and adult periodontitis are com-
pared with those from patients with refractory and early onset peri-
In figure 3 two additional patient groups, those with RefPodontitis. Standard error bars are shown. cmp  counts per minute.
and EOP, are considered. These more aggressive forms of
systemic monocyte responsiveness trait, as determined by the
amount of PGE2 secreted in culture, could be correlated to the
severity of the condition and the level of PGE2 present within
the GCF. This experiment was conducted by generating LPS-
dose vs. PGE2-response curves for each subject and simultane-
ously measuring the PGE2 level within the GCF, averaging
over four sites per subject. To permit easy comparison among
patients, the data are shown for the monocytic PGE2 level at
only one suboptimal LPS concentration (0.03 mg/mL) vs. the
GCF-PGE2 level. These data are developed sequentially in fig-
ure 3. It should be noted that the monocytic secretion of IL-
1b and TNF-a has also been investigated in some of these
patients and is reported on elsewhere [8, 9, 16]. These data are
not presented in this report but in general show the same trend
as PGE2 responses.
Figure 3. Relationship between systemic monocytic prostaglandinMonocytic and GCF-PGE2 Levels in Otherwise Healthy Adults
E2 (PGE2 ) release upon challenge with lipopolysaccharide (0.03with Periodontitis and in CD14-Deficient Patients
mg/mL, from Porphyromonas gingivalis) and local levels of PGE2
in gingival crevicular fluid (GCF) in CD14-deficient subjects (l;Figure 3 shows the amount of monocytic PGE2 secreted in
paroxysmal nocturnal hemoglobinuria; n  13); in periodontallyresponse to P. gingivalis LPS (0.03 mg/mL) in healthy persons
healthy patients (
   
   
   
   
; n 34); in patients with gingivitis/mild periodon-
and in patients with AP (AAP stages I–II or III–IV) or parox- titis ( ; American Academy of Periodontology [AAP] stage I or II;
ysmal nocturnal hemoglobinuria. As can be seen, the amount n  36), moderate/severe adult periodontitis ( ; AAP stage III or
IV; n  30), refractory periodontitis (s; AAP stage V; n  24), orof monocytic PGE2 secreted in subjects with AP at AAP stages
early onset periodontitis (1; EOP; n  22); in patients with insulin-I–II (61.0 { 4.6 ng/mL) or III–IV (68.4 { 7.4 ng/mL) and
dependent diabetes mellitus and either gingivitis/mild AP (Y; AAPin healthy individuals (65.9 { 9.0 ng/mL) is virtually identical.
stage I or II; n  10) or moderate/severe AP ( ; AAP stage III or
We have previously referred to this response as a normal mono- IV; n  29); and in patients with terminal-dentition-stage AP (.; n
cytic secretory trait, or MfN. In comparison, the patients with  8) or terminal-dentition-stage EOP (q; n  8). Standard error bars
are shown.paroxysmal nocturnal hemoglobinuria have a significantly re-
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periodontal disease are associated with a shift in the monocytic 297.4 ng/mL) groups, as compared with levels among subjects
with moderate/severe AP (58.7 { 11.2 ng/mL; P  1005) orresponses. The amount of PGE2 secreted by monocytes from
subjects with RefP (94.4 { 11.7 ng/mL) or EOP (90.0 { 7.6 EOP (102.6 { 18.4 ng/mL; P  .001). Furthermore, LPS-
stimulated monocytic PGE2 levels for both TD-AP (145.0 {ng/mL) is significantly greater than that in healthy subjects or
patients with AP (P  .01, vs. pooled MfN subjects). This 20.7 ng/mL) and TD-EOP (180.6 { 47.6 ng/mL) patients are
greater than those for patients with moderate/severe AP (68.4systemic monocytic trait appears stable, since the level of secre-
tion remains elevated in controls with AP following treatment { 7.4 ng/mL; P  .001) or EOP (90.0 { 7.6 ng/mL;
P  .05). It is interesting to note that the relationship between[6], and the term hyperresponsive monocytic trait (or Mf/ trait)
has been used [11] to characterize this upregulated systemic local and systemic PGE2 response appears to maintain a similar
ratio or slope as the severity of disease escalates.monocyte characteristic.
The highly significant elevations in levels of GCF-PGE2 Finally, figure 3 illustrates the responses of the subjects with
IDDM-AP, subdivided by AAP stages (I–II and III–IV). These(RefP: 104.0 { 13.1 ng/mL; EOP: 102.6 { 18.4 ng/mL) rela-
tive to those in pooled subjects with AP of AAP stages I–IV data from an earlier publication [8] demonstrate a significant
4.2-fold elevation in GCF-PGE2 level in a comparison of dia-(P .00006 for RefP and P .0007 for EOP) also are consis-
tent with the rapidly progressive and active clinical courses of betics with AP of AAP stage I–II (183.2 { 76. ng/mL) to
periodontally matched, nondiabetic subjects (43.3 { 8.1these conditions. These subjects are at high risk for clinical
breakdown compared with the risk for subjects with AP. It is ng/mL) (P  .003). A higher, 7.4-fold elevation is observed
in a comparison of GCF-PGE2 levels for patients with IDDM-interesting that the ratio between systemic and local responses
remains identical for these subjects, in contrast with the ratios AP of AAP stage III–IV (319.1 { 62.2 ng/mL) and those for
periodontally matched nondiabetics (42.9 { 11.9 ng/mL)for subjects with AP. This can be noted in figure 3, in which
all of these diseased subjects fall on the same linear regression (P  .0002). Among diabetics, the GCF-PGE2 level is signifi-
cantly elevated for those with moderate-severe periodontitis,line. In this regard, the observed GCF-PGE2 level might be
anticipated on the basis of the systemic monocytic response as compared with that for patients with gingivitis/mild peri-
odontitis (P  .01). Diabetics as a group show a 13.8-foldtrait.
The combination of these five patient groups establishes a elevation in GCF-PGE2 level over the level for periodontally
healthy persons and a 6.6-fold elevation over that for nondia-clear, positive association between local and systemic PGE2
responses, as evident in figure 3. Using the mean values from betics with moderate-severe periodontitis (P  .00001). These
data clearly suggest that IDDM results in a dramatic elevationthese five patient groups as point estimates to compute the
linear regression curve for the association between GCF-PGE2 in the GCF-PGE2 levels, irrespective of periodontal status.
and monocytic (‘‘mono-’’) PGE2 (at 0.03 mg of P. gingivalis
LPS per mL) provides the following equation:
Discussion
Data regarding cultured peripheral blood monocytes fromLog10[GCF-PGE2 ng/mL]  0.01 1 [mono-PGE2 ng/mL]
high-risk patients (with EOP, RefP, IDDM-AP, and TDP) sug-/ 1.0, with r  0.997 and r2  0.995 (P  .0001). gest that the locally elevated GCF-PGE2 levels are associated
with a systemically upregulated monocytic PGE2 trait. These
Thus, incremental changes in the systemic monocytic response observations confirm and extend previous investigations sug-
are reflected as exponential changes in the local GCF-PGE2 gesting that patients with RefP [20, 21] and EOP [22] have
levels. considerably elevated monocytic PGE2 levels as compared with
those in patients with AP. In 1989 Garrison and Nichols [20]
demonstrated that LPS-stimulated monocytes from ‘‘periodon-
Monocytic and GCF-PGE2 Responses in TDP and IDDM-AP
Figure 3 also illustrates the local and systemic responses of titis-susceptible’’ subjects secreted twofold to threefold more
PGE2 than those from ‘‘periodontitis-resistant’’ patients. In thispatients with severe AP and generalized EOP at a terminal
dentition (TD) stage. The periodontal status of these subjects context the term susceptible was used to describe cases of RefP,
whereas the term resistant referred to patients with untreatedis reflected in the severity scores (mean clinical attachment
levels, only among sites for which the scores were ⁄4 mm) periodontitis who had poor plaque control and little or no dis-
ease. Shapira et al. [22] observed significantly greater basalof 6.03 { 0.33 mm for TD-AP and 6.11 { 0.42 mm for TD-
EOP. Recent data by Salvi et al. [9] have provided evidence levels (no LPS challenge) of monocytic inflammatory media-
tors, including PGE2 , in 28 patients with EOP than in periodon-that patients with TD-AP and TD-EOP have exaggerated GCF
and monocytic secretions of several inflammatory mediators, tally healthy controls. Furthermore, these investigators found
a consistent threefold to fivefold greater monocytic PGE2 secre-including PGE2 , as compared with secretions in patients with
AAP type IV periodontitis. Data from that investigation illus- tion throughout the LPS dose-response curve than that in con-
trol subjects. Thus, these earlier observations have now beentrate that the GCF has unexpectedly high levels of PGE2 in
both TD-AP (970.5 { 154.7 ng/mL) and TD-EOP (749.4 { replicated and expanded by the current report of 209 subjects,
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and collectively they provide compelling evidence that the sys- which is consistent with the established role of CD14 as a
high-affinity LPS–LPS binding protein receptor. This Mf0temic, peripheral blood monocyte is upregulated with regard
to its secretory capacity in conditions such as EOP, RefP, phenotype is logically a consequence of this membrane-recep-
tor deficiency. Although a few of these subjects were takingIDDM-AP, and TDP.
The hypersecretory phenotype (Mf/) occurs spontaneously systemic steroids to manage the clinical course of paroxysmal
nocturnal hemoglobinuria, excluding these subjects from thisand throughout the LPS dose-response range. The systemic
monocyte in RefP and EOP appears to be ‘‘primed’’ in that it dataset does not significantly alter the data, and the monocytic
responses in this culture assay are not different in a comparisonsynthesizes greater amounts of PGE2 in culture, even in the
absence of LPS challenge, as compared with amounts synthe- of patients taking steroids and those who were not (details
appear in [15]).sized in healthy controls or subjects with AP. Although not
shown in figure 2, additional findings by Salvi et al. [8] indicate In contrast to the molecular mechanisms responsible for the
observed Mf/ trait in EOP, RefP and IDDM-AP are not pres-that systemic monocytes in subjects with IDDM also appear
to be primed in the circulation. Freshly isolated unstimulated ently understood. Nonetheless, several potential explanations
have emerged and include the following.peripheral blood monocytes from patients with IDDM secrete
higher amounts of PGE2 than do those from nondiabetic con- (1) Mølvig and colleagues [23] have demonstrated stable
interindividual differences in monocytic release of IL-1b, TNF-trols. Basal monocytic PGE2 levels in diabetics with gingivitis/
mild periodontitis (75.0 { 32.0 ng/mL) and moderate/severe a, and PGE2 in response to LPS. Thus, there is a wide spectrum
in the magnitude of the inflammatory-mediator release amongperiodontitis (104.0 { 21.0 ng/mL) are higher than those in
control subjects with moderate/severe AP (57.1 { 5.6 ng/mL). different individuals. This response trait appears to be relatively
stable over short periods of time.Thus, patients with EOP, RefP, and IDDM-AP all appear to
have basal or resting-state monocytic responses that are ele- (2) One possible explanation for the large variance in the
magnitude of mediator secretion in the normal population isvated with regard to PGE2 production.
It is significant that AP, the most common periodontal condition that certain genetic polymorphisms are associated with a hyper-
secretory or hyposecretory monocytic trait (see [24, 25] for(accounting for 85% of all periodontal cases), is associated
with a normal monocytic response (MfN), as determined with or review). Several of these stable genetic polymorphisms have
been associated with increased severity of infectious or in-without LPS challenge. Thus, cross-sectionally it would appear
that subjects with AP have no evidence of monocytic abnormali- flammatory conditions, including cerebral malaria [25], muco-
cutaneous leishmaniasis [26], and psoriasis [27]. These poly-ties or ‘‘priming’’ as a consequence of genetic background or
environmental exposures such as infection, including periodontal morphisms have been identified for IL-1 [28] and TNF-a [29],
both of which are capable of autocrine upregulation of mono-disease. This would suggest that in AP, the microbial challenge
that occurs systemically, albeit transient in nature, is not a suffi- cytic PGE2 secretion. Thus, elevated PGE2 secretion may be
an indirect indicator or consequence of enhanced release of IL-cient challenge to cause an upregulated, steady-state priming of
the systemic peripheral blood monocyte. 1 or TNF-a.
(3) Allelic variants in the IL-1 gene cluster result in alteredIt is not clear from these cross-sectional data whether, during
episodes of acute disease progression, patients with AP have IL-1b response, and certain polymorphisms may be related to
certain severe forms of AP [30]. Certain environmental expo-a transiently upregulated monocyte phenotype. However, the
close coupling of the local and systemic PGE2 responses, as sures, such as smoking, may override any genetic contribution
to disease expression. It is not known whether the increaseddemonstrated in figure 3, would suggest that previously re-
ported transient elevations of mean GCF-PGE2 levels (to 113.4 disease susceptibility and high PGE2 levels in the four high-
risk patient groups in this study are a consequence of a hyperse-{ 9.0 ng/mL) [6] that occur during longitudinal episodes of
disease progression are associated with a monocytic response cretory IL-1 and/or TNF-a polymorphism.
(4) Environmental exposures such as smoking have beenof 105 ng/mL (as computed with use of the regression function
shown above). As can be seen, this value would theoretically demonstrated to enhance monocytic PGE2 secretion [31].
Unfortunately, this important risk factor (see [32] for review)place the monocytic response in cases of AP breakdown equal
to that in cases of RefP and EOP involving Mf/ patients. was not uniformly determined for each subject in this study.
Many of the subjects with RefP and three of the 16 subjectsOn the basis of the elevated GCF-PGE2 levels during disease
progression, these data suggest that during these short periods with TD-AP were smokers. Thus, smoking is one important
potential mechanism for induction of a steady-state Mf/of active attachment loss, the patients with AP probably have
a transient Mf/ phenotype. This concept is further substanti- phenotype.
(5) Metabolic lipid dysregulation upregulates monocytic re-ated by the observed hyperresponsive shift in the monocytic
trait in TDP cases, as discussed below. sponses to LPS challenge [33, 34]. Specifically, high levels of
low density lipoprotein prime monocytes to secrete elevatedMonocytes from the subjects with paroxysmal nocturnal he-
moglobinuria who lack glycerolphosphatidyl inositol–an- amounts of PGE2 subsequent to challenge. Unfortunately,
blood lipid chemistries were not included in our data collection.chored CD14 demonstrate a reduced PGE2 secretory capacity,
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